Accordingly, we hypothesize that aggressive PCa with high m6Avalue might be more vulnerable to inhibitors of CDK4, ALK, TOP1 and others, directing novel therapeutic strategies that warrant further exploration. This evidence concerns the gene CDK4 and posterior cortical atrophy.